Latest news with #BiohavenLtd
Yahoo
29-05-2025
- Business
- Yahoo
Biohaven Ltd. (BHVN)'s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy
Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and BHV-1300, at its 2025 R&D Day in New Haven. BHV-1400, a first-in-class TRAP degrader, achieved up to 81% reduction in galactose-deficient IgA1 (Gd-IgA1), the key driver of IgA nephropathy (IgAN), after a single subcutaneous dose, with effects lasting for weeks. A patient viewing their medical diagnosis on a digital healthcare ecosystem. Unlike traditional immunosuppressive treatments, BHV-1400 precisely eliminates pathogenic Gd-IgA1 while sparing healthy antibodies (IgA, IgG, IgE, IgM), preserving overall immune function and offering a superior safety profile. This selectivity sets it apart from complement and BLyS/APRIL inhibitors, which can compromise broader immunity. Encouraged by these results, Biohaven Ltd. (NYSE:BHVN) will launch a pivotal IgAN trial in 2026 using the urine protein-creatinine ratio as an accelerated approval endpoint. Simultaneously, BHV-1300, targeting IgG-mediated diseases like Graves' Disease, demonstrated rapid, deep, and sustained total IgG reductions of up to 87% in Phase 1, with flexible dosing for acute and chronic management. Both therapies were well-tolerated, with no serious adverse events. Biohaven Ltd. (NYSE:BHVN) plans pivotal trials for BHV-1300 in Graves' Disease in the second half of 2025, reinforcing its leadership in precision immunology. While we acknowledge the potential of BHVN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BHVN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)
Optimized subcutaneous (SC) administration of BHV-1400 achieved rapid, deep, selective, and sustained lowering of Gd-IgA1, differentiating Biohaven's leading TRAP degrader for IgAN from the complement and BLyS/APRIL inhibitor competition. Up to 81% reduction of Gd-IgA1 was observed, with reductions from baseline sustained for weeks after a single SC dose administration. BHV-1400 brings precision immunology to the treatment landscape of IgAN as it was rationally designed to selectively remove galactose-deficient IgA1 (Gd-IgA1), the pathogenic antibody driver of the disease while sparing healthy antibodies IgA, IgG, IgE, and IgM. Preservation of immunoglobulins, the complement system, and cell-mediated and humoral immunity offers key differentiation against immunosuppressive BLyS/APRIL inhibitors, complement inhibitors, and budesonide. Based upon the rapid and deep reductions of Gd-IgA1 observed with subcutaneous BHV-1400, Biohaven plans to study BHV-1400 in patients with IgAN, initiating a pivotal trial in 2026 using urine protein-creatinine ratio (UPCR) as a surrogate endpoint for accelerated approval. Optimized SC administration of BHV-1300 has continued to demonstrate rapid, deep, and sustained lowering of total IgG in Phase 1 studies. Recently generated clinical data shows that BHV-1300 achieved rapid, deep, and sustained lowering of total IgG, with reductions up to 87%. Median maximum reductions of 83% were observed within 18 days of the first subcutaneous dose. The range of IgG reductions possible with varying dosing paradigms of BHV-1300 allows for tunable dosing regimens tailored for acute and chronic disease management, with higher doses for acute disease management and lower, less frequent dosing for chronic disease management. Based upon the rapid and deep reductions of IgG and favorable tolerability profile observed with BHV-1300, Biohaven plans to study BHV-1300 in patients with Graves' Disease and initiate pivotal trials in 2H 2025. NEW HAVEN, Conn., May 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted the success of its first MoDE™ and TRAP™ degraders in achieving key target pharmacodynamic endpoints and announced plans to initiate pivotal trials in Graves' Disease and in IgA nephropathy in 2H 2025 and 1H 2026, respectively at Biohaven's 2025 R&D Day, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. The presentation slides from Biohaven's R&D day for the TRAP and MoDE degraders and its other platforms will be available on the Events and Presentations page of the Biohaven website just prior to their presentations. BHV-1400, the Company's potential first-in-class galactose-deficient IgA1 (Gd-IgA1) TRAP degrader for the treatment of IgA nephropathy (IgAN) achieved deep, rapid, and sustained reductions in Gd-IgA1. In the Phase 1 study, a single dose of BHV-1400 was subcutaneously administered at a dose of 500 mg and achieved rapid, deep and sustained reductions in Gd-IgA1 of up to 81%, with a median reduction of 66% (Figure 1). Reductions occurred within hours of each dose, were progressive, and were sustained for weeks after a single dose administration. Effects were selective, with no significant reductions observed in other immunoglobulins: IgA, IgG, IgE, or IgM. Dr. Jonathan Barratt, the Mayer Professor of Renal Medicine at University of Leicester and leading expert in the treatment of IgAN, commented on the new Phase 1 data, "The reason I am excited about BHV-1400 is because it specifically targets the fundamental abnormality in IgA nephropathy while leaving the rest of the immune system untouched. It has the potential to take away the major driver for immune complex formation while leaving other antibodies completely unaffected, which means it has efficacy with unrivaled safety." IgA nephropathy is the leading cause of glomerular disease globally and is commonly diagnosed in individuals in their second and third decades of life, with most individuals progressing to renal failure over the ensuing 10-15 years. As a disease of the immune system, IgA nephropathy frequently returns even after renal transplant. While the 2021 Kidney Disease Improving Global Outcomes (KDIGO) treatment guidelines recommended only standard chronic kidney disease treatments, the 2024 draft guidelines emphasize the importance of treating the underlying immune disease by removing aberrant forms of IgA. "Galactose deficient IgA1 is the fundamental abnormality in IgA nephropathy," Dr. Barratt explained, "It's a group of IgA molecules that have changes to the sugars on the IgA1 hinge region that fundamentally change the way this antibody behaves. It promotes immune complex formation and it's these immune complexes that cause glomerular injury and damage and promote loss of kidney function." BHV-1400's selective approach has the potential to offer an improved safety profile compared to broadly immunosuppressive agents. BHV-1400 has been safe and well-tolerated across the ongoing Phase 1 study. Most adverse events (AEs) were mild and self-resolving, there were no discontinuations due to AEs related to study drug, and there were no serious or severe AEs related to drug. There were no clinically significant increases in ALT, AST or bilirubin, no clinically significant reductions in albumin and no clinically significant increases in cholesterol relative to placebo over the 4-week dosing period. There were no clinically significant reductions in other immunoglobulins including IgG, IgA, IgE, or IgM relative to baseline. With regards to the applicability of Phase 1 data in healthy volunteers to patients with IgAN, Dr. Barratt added, "It's not that the Gd-IgA1 is subtly different, it's the same in both (healthy volunteers and patients with IgAN), but in patients, they just have an excess quantity. And so, what I believe is that because you're seeing a suppressed Gd-IgA1 in healthy subjects you are going to see the same in patients with IgA nephropathy, and indeed that's what some of the drugs targeting BAFF and APRIL have shown. They presented data in their healthy volunteer population that was precisely replicated when they went in to patients." BHV-1400 fundamentally differentiates from alternative approaches by virtue of its precision. While agents targeting the glucocorticoid receptors may have steroid-like side effects, those targeting complement require vaccination for encapsulated bacterial infections, and B-cell-directing therapies cause reductions in all isotypes of immunoglobulin, potentially increasing long-term infection risk. Based upon the rapid and deep reductions of Gd-IgA1 observed with SC dosing of BHV-1400, Biohaven plans to study BHV-1400 in patients with IgAN and initiate pivotal trials in 2026 using UPCR surrogate endpoint via the accelerated approval pathway. At its R&D Day, Biohaven also released new positive data from its completing Phase 1 study of its leading MoDE degrader, BHV-1300, that targets IgG for removal. In the Phase 1 multiple-dose study, SC administered BHV-1300 achieved IgG reductions up to 87%. Median maximum reductions of 83% were achieved within 18 days (Figure 2). Biohaven recently reported the 1000 mg weekly dose achieved rapid, deep and sustained reductions in total IgG of up to 84%, with a median reduction of 80% by Week 4 (Figure 2). Reductions at all doses occurred within hours of administration, were progressive, and effects were durable between dosing intervals. The range of IgG lowering enabled by different dose levels of BHV-1300 offers tunability and flexibility in dosing paradigm, with higher doses planned for management of acute conditions, and lower, less frequent dosing planned for the management of chronic disease. BHV-1300 has been safe and well-tolerated in subcutaneous doses up to 2000 mg with no clinically significant increases in ALT, AST, or bilirubin, no clinically significant reductions in albumin, and no clinically significant increases in cholesterol over the four-week dosing period relative to placebo. There were no clinically significant reductions in IgG3, IgA, IgE, or IgM relative to baseline. Most AEs were mild and self-resolving, and there were no serious or severe AEs. BHV-1300 is a potential first-in-class novel small molecule MoDE degrader in development for the treatment of IgG-mediated diseases, such as Graves' Disease. It is designed for self-administration via an easy-to-use and patient-friendly autoinjector. Biohaven plans to study BHV-1300 in patients with Graves' Disease and initiate a pivotal trial in 2H 2025. Tova Gardin, MD, MPP, Chief Translational Officer at Biohaven, commented, "Our lead MoDE and TRAP degraders, BHV-1300 and BHV-1400, deliver on the promise of ground-breaking chemistry, demonstrating unrivaled selectivity, and profound depletion of potentially disease-causing proteins. With the selectivity of the platform and the initial profile observed in Phase 1, we aim to bring precision immunology to patients with safe and effective treatments that target the core of disease biology. We are incredibly proud of our innovative, agile, and dynamic team that has catalyzed a first of its kind extracellular degrader technology from bench to the clinic. Driven by patient need and leading-edge, mechanistically precise science, Biohaven remains focused on delivering the promise of precision therapies to patients with immune-mediated disease." About BHV-1400BHV-1400 is a potential first-in-class Gd-IgA1 TRAP degrader, rationally designed to leverage the body's natural hepatic clearance mechanisms to selectively target and remove Gd-IgA1, the underlying cause of the IgA nephropathy and IgA vasculitis. BHV-1400 spares IgG, IgA, IgE, and IgM to preserve patient immune protection against bacteria, viruses and parasites. The results of the ongoing Phase 1 study confirm that BHV-1400 produces deep reductions in Gd-IgA1 within hours, is selective, sparing other immunoglobulins, is tunable, and is safe and well-tolerated. About BHV-1300BHV-1300 is a small molecule and potential first-in-class extracellular IgG degrader, rationally designed to leverage the body's natural hepatic clearance mechanisms to selectively target and remove IgG1, IgG2, and IgG4, the underlying cause of many immune-mediated diseases. BHV-1300 spares IgG3 to preserve patient immune protection against bacteria, viruses and parasites. The results of ongoing Phase 1 study confirm that BHV-1300 produces deep reductions in total IgG, is selective, sparing IgG3, is tunable, and is safe and well-tolerated. About BiohavenBiohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; MoDE™ and TRAP™ extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. For more information, visit Forward-looking Statements This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "potential first-in-class", "potentially", "groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials, including the studies of BHV-1300 and BHV-1400; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. MoDE and TRAP are trademarks of Biohaven Therapeutics Ltd. Investor Contact:Jennifer PorcelliVice President, Investor (201) 248-0741 Media Contact:Mike BeyerSam Brown (312) 961-2502 View original content to download multimedia: SOURCE Biohaven Ltd. Sign in to access your portfolio
Yahoo
25-04-2025
- Business
- Yahoo
Jim Cramer Says Biohaven (BHVN) Is 'Too Cheap' and He's a Buyer at $21
We recently published a list of . In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other stocks that Jim Cramer discussed recently. On Tuesday, Jim Cramer, host of Mad Money, offered his perspective on the day's market rally as he delved into the impact of the ongoing dynamic between President Donald Trump and Federal Reserve Chair Jerome Powell. 'All day, I heard that today's rally was just a bear market rally, okay? That it was a phony spike, and the market will go right back down the moment the president posts that there'll be no compromise on tariffs. Who knows, maybe Fed Chief Jay Powell should be deported.' READ ALSO: 9 Stocks on Jim Cramer's Radar and Jim Cramer's Thoughts on These 5 Stocks. However, Cramer pointed out that the tone shifted significantly just after the market closed. In his words, 'We get incredible news that is sure to drive this market higher.' The news came directly from the President, who clarified that he had no intention of firing Powell, a rumor that Cramer identified as a major factor in the prior day's market slide. Trump's statement, 'Never did, never will,' regarding any plans to remove Powell effectively erased the cloud of uncertainty that had been hanging over the markets. Given this reversal, Cramer questioned whether the rally could still be called a bear market bounce. In his view, it now looked like something more substantial. He explained that real recoveries are often mischaracterized at first. According to Cramer, they typically begin with what appear to be bear market rallies, short-lived, suspicious upticks that many investors brush off due to repeated disappointments in the past. He stressed that the early stages of genuine market turnarounds are often marked by disbelief and hesitation, with only the boldest or most reckless traders recognizing their potential early on. He added: 'Now look, just because the President doesn't want a constitutional crisis and is going to keep Powell doesn't mean we have more to go on. For example, there's been no sign of change from the administration on the trade wars.' For this article, we compiled a list of 15 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on April 22. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey's database of over 1,000 hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 41 A caller asked for Cramer's take on Biohaven Ltd. (NYSE:BHVN). Here's what Mad Money's host had to say: 'Alright, first, in pure disclosure, Biohaven, I'm working with them. They've bought a drug from me, that I made for me, and a terrific guy, Larry Newman, Dr. Newman, to help solve tinnitus so I always want to tell people that. The stock at $21, I think, therefore, is too cheap. But you might say, oh, that's just Jim talking because he sold his drug to them. But no, I think the stock is very cheap, and Vlad Coric, who's the CEO, I think, is really terrific. So I would be a buyer of the stock.' Biohaven (NYSE:BHVN) focuses on discovering, developing, and bringing to market therapies in immunology, neuroscience, and oncology. Overall, BHVN ranks 8th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of BHVN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BHVN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of . In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over President Trump's tariffs earlier this month, but the rollercoaster is not over just yet. All three major indexes closed last week in the red, with the Dow and NASDAQ both dipping over 2%, and the broader market down more than 1%. Even though markets remain closed on April 18 for Good Friday, the general consensus is that the worst of the trade war headlines might be dying down. Marko Papic, chief strategist of geomacro strategy at BCA Research, remains cautiously optimistic, noting that while the idea of President Trump striking 90 trade deals in 90 days sounds ambitious, they will likely be small, symbolic wins that still help calm markets. That said, volatility is expected to continue, and Papic predicts the broader market could dip again before bouncing back, potentially giving investors a buying opportunity. Investors are deep in earnings season right now, and some of Wall Street's biggest banks have reported solid first-quarter results. A big part of their success came from their trading desks, which cashed in on the recent market volatility, especially in equities. However, despite strong numbers on paper, bank CEOs remain cautious and are hesitant to make big moves right now because of the market uncertainty. The US dollar also just had its worst weekly performance since 2022. Meanwhile, investors are playing it safe and rapidly buying bonds, which pushed the 10-year Treasury yield down to around 4.28%. While some investors are seeing the current market dip as a buying opportunity, Daniel Von Ahlen from GlobalData TS Lombard says otherwise. He believes the risks of a recession are being seriously underestimated. Even though Trump's recent tariff halt gave markets a bit of a boost, Ahlen thinks that bounce will not last. In his view, this is not the time to scoop up stocks on the cheap, he is actually advising people to sell into rallies and avoid the usual buy-the-dip strategy. Ahlen suggests getting a bit more cautious and selective. Instead of jumping into the whole market, he recommends focusing on defensive sectors, like utilities, consumer staples, and healthcare, that tend to hold up better in downturns. The market uncertainty is reflected in ETFs as well, which are often considered wiser investment options due to active management strategies and lower risk compared to individual investing. For example, the Guru ETF is down 8.30% year-to-date as of April 18. However, over the last 12 months, the fund has posted share price returns of 13.38%. Similarly, five-year share returns stand at an impressive 51.57%. GURU gives retail investors a way to tap into the top stock picks of major hedge funds at a relatively low 0.75% expense ratio. It offers a more affordable and flexible way to try and beat the broader market using expert insights. So, let's take a look at the best Guru stocks to buy. A pharmacist in a white coat with a range of drugs on shelves behind her. For this article, we looked up the GURU ETF, which had 82 holdings as of April 18. Next, we manually searched for the average upside potential of each stock and selected 11 stocks with the highest values. The list below is ranked in ascending order of the upside potential as of April 18. We have also mentioned the hedge fund sentiment as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 41 Average Upside Potential: 213.78% Biohaven Ltd. (NYSE:BHVN) is a Connecticut-based biotech company, developing treatments for neuroscience, immunology, and cancer. The company is working on late-stage candidates for epilepsy, depression, migraines, spinal muscular atrophy, obesity, and neurodegenerative diseases like Alzheimer's and Parkinson's. BHVN ranks 1st on our list of the best Guru stocks to buy. On March 7, Piper Sandler maintained an Overweight rating on Biohaven Ltd. (NYSE:BHVN) with a $76 price target. The investment firm remains confident in Biohaven, highlighting the company's solid R&D pipeline, especially BHV-1300, which showed strong IgG-lowering results with a clean safety profile in early trials. With several milestones expected in 2025, analysts see plenty of room for growth and believe the stock is slightly undervalued right now. In Q4 2024, Biohaven Ltd. (NYSE:BHVN)'s R&D spending increased to $167.5 million from $134.8 million in the prior-year quarter. This reflects the company's growing pipeline, with more advanced clinical and preclinical trials underway. However, non-cash share-based compensation fell by $2 million since no new equity awards were granted in Q4 2024. Biohaven posted a net loss of $186.8 million for the fourth quarter, up from a $144.8 million loss in the same period last year. According to Insider Monkey's fourth quarter database, 41 hedge funds held long positions in Biohaven Ltd. (NYSE:BHVN), compared to 42 funds in the preceding quarter. Overall, BHVN ranks 1st among the 11 Best Guru Stocks to Buy According to Wall Street Analysts. While we acknowledge the potential of BHVN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BHVN but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
05-04-2025
- Health
- Yahoo
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, "We are excited to highlight our clinical and scientific progress at the AAN Annual Meeting, including 3 oral presentations and 10 poster presentations, emphasizing Biohaven's innovation, leadership and commitment to developing potential first-in-class therapies for debilitating neurological disorders with inadequate or no treatment options. The team at Biohaven has been working urgently to advance our next-generation medicines as we aim to transform the way these diseases are treated. We look forward to achieving critical value-creating milestones throughout 2025 as we advance these assets across multiple high unmet need indications." The complete list of Biohaven's accepted abstracts is below. Full abstracts can be viewed online at Oral Presentations: BHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson's Disease Mouse ModelS4: Movement Disorders: Basic ScienceSunday 4/6/25 1:00-3:00pm (2:00-2:12pm) Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and MigraineS11: PainMonday 4/7/25 11:15am-12:15pm (11:51am-12:03pm) Novel Bispecific Degrader BHV-1310 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models including Nonhuman PrimatesS18.009Monday 4/7/25 1:00-3:00pm (2:36-2:48pm) Poster Presentations: A Qualitative Assessment of the Epilepsy Patient Experience Through Social Media and Web-Based ForumsP2: Epilepsy/Clinical Neurophysiology (EEG): Clinical Outcomes in EpilepsySunday 4/6/25 8:00-9:00am Novel Bispecific Degrader BHV-1310 Eliminates Intravascular and Interstitial IgG within Multiple Organs and Anatomical Structures Including the Neuromuscular JunctionP4: Autoimmune Neurology: Peripheral Autoimmune NeurologySunday 4/6/25 5:00-6:00pm Comparative Effectiveness of Troriluzole Versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching MethodsP6: Movement Disorders: Ataxia 1Monday 4/7/25 11:45-12:45 BHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of MigraineP7: Headache: Advances in Headache Treatment 1Monday 4/7/25 5:00-6:00pm Re-weighting MDS-UPDRS Parts II and III Items to Improve Assessment of Motor Decline in Untreated Parkinson's DiseaseP7: Movement Disorders: Parkinson's Disease ManagementMonday 4/7/25 5:00-6:00pm Re-weighting MDS-UPDRS Part II and PDQ-39 Items to Detect Maximal Decline in Activities of Daily Living in Untreated Parkinson's diseaseP7: Movement Disorders: Parkinson's Disease ManagementMonday 4/7/25 5:00-6:00pm A Modern Design for a Phase 2/3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic SeizuresP8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical TrialsTuesday 4/8/25 8:00-9:00am BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 StudiesP9: General Neurology: New, Potential, and Innovative Treatments 1Tuesday 4/8/25 11:45am-12:45pm Phase 1 Multiple Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel ActivatorP9: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms and PharmacologyTuesday 4/8/25 11:45am-12:45pm Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)P12: Movement Disorders: Ataxia 2Wednesday 4/9/25 11:45-12:45 Posters and presentations will be available on the Posters and Presentations page after the conference at About Biohaven Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate", "potential first-in-class", "disrupt", "potentially revolutionize", "groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor Contact:Jennifer PorcelliVice President, Investor (201) 248-0741 Media Contact:Mike BeyerSam Brown (312) 961-2502 View original content to download multimedia: SOURCE Biohaven Ltd. Sign in to access your portfolio
